Asian biomedical accelerator will cooperate with five major pharma companies

13 September 2018

GMP News

Asia’s largest biomedical accelerator, H. Spectrum, announced last weekend that it will collaborate with five major companies on a range of innovative medical technologies during the Trans 2018 digital health conference in Taipei (Taiwan).

Global giants Bayer, Merck, and GE Ventures have come aboard, and will collaborate with H. Spectrum on applications of artificial intelligence, and to explore new opportunities with U.S. tech company NVIDIA, according to Liberty Times.

Taiwan’s H. Spectrum is the largest biomedical startup accelerator in Asia, and strives to foster entrepreneurship through creative advisory. The accelerator recently outlined an international expansion plan, through which it will collaborate with Wisconsin biotech organizations BioForward, Sutter Health, and Lab Central.

H. Spectrum signed the strategic partnership during the Trans 2018 digital health conference, which was organized by H. Spectrum and Foxconn. The conference brought together some of the world’s most influential biomedical, venture capital, and medical companies.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more